Market News

Insider Trades: Cleveland-Cliffs Vs ArriVent BioPharma Insider Trades: Cleveland-Cliffs Vs ArriVent BioPharma

U.S. stocks closed higher on Thursday, showcasing notable insider trades that imply confidence or bargain views. Insider purchases are not sole investment indicators, but they can offer conviction.

Here’s a look at some recent noteworthy insider purchases:

Vera Therapeutics

  • Insider: Vera Therapeutics, Inc. VERA Director Maha Katabi acquired 161,290 shares at an average price of $31.00, totaling around $5 million.
  • News: Vera Therapeutics priced its upsized public offering of 8,064,517 class a common stock at $31 per share.
  • What Vera Therapeutics Does: Vera Therapeutics Inc is a clinical stage biotechnology company focused on transformative treatments for serious immunological diseases.

ArriVent BioPharma

  • Insider: ArriVent BioPharma, Inc. AVBP 10% owner HHLR ADVISORS, LTD. acquired 4,484,672 shares at an average price of $18.00, totaling around $10 million.
  • News: ArriVent BioPharma priced its upsized initial public offering of 9,722,222 common shares at $18 per share.
  • What ArriVent BioPharma Does: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines for cancers.

KalVista Pharmaceuticals

  • Insider: KalVista Pharmaceuticals, Inc. KALV 10% owner Nimish Shah bought 88,099 shares at an average price of $14.47, totaling around $1.27 million.
  • News: KalVista Pharma announced publication of first oral factor XIIa data in Frontiers in Pharmacology in December.
  • What KalVista Pharmaceuticals Does: KalVista Pharmaceuticals Inc focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases.

Cleveland-Cliffs

  • Insider: Cleveland-Cliffs Inc. CLF Director Ron Bloom bought 25,000 shares at an average price of $20.24, spending around $506,095.
  • News: Cleveland-Cliffs reported quarterly adjusted losses of five cents per share, 25% below analyst expectations of losses of four cents.
  • What Cleveland-Cliffs Does: Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America with one reportable segment: Steelmaking.
See also  Unraveling Tesla’s Current Stock Conundrum: Time to Seize the Moment?

 

Check This Out: Top 5 Energy Stocks That May Crash This Quarter